vivo by giving animals with silver nitrate induced secondary amyloidoses different fatty acids or fatty acid combination after 25 weeks of treatment animals given epax1050 or approximately pure dha did not develop amyloid to the same extent as animals given oleic acid in fact only one animal in the dha groups epax1050 and pure dha developed amyloid after silver nitrate injections compared to 3 animals in the oleic acid group even if the number of animals used is too small for a statistical evaluation the trend is quite clear meaning that dha or high dha concentrates seems to prevent against development of amyloid the congruence between in vitro derived data and in vivo data is striking indicating a novel therapeutic modality to diseases etc the present findings indicate a novel therapeutic modality to diseases caused by amyloid deposition the treatment could be preventive reducing the propensity of fibril formation as well as therapeutic in situations with established amyloid finally the results strongly support the use of a medicinal product a pharmaceutical composition a food stuff or a food supplement comprising a fatty acid composition comprising at least dha for the treatment and or prevention of amyloidos related diseases such as for instance alzheimer 39 s disease iga nephropathy and type ii diabetes the invention shall not be limited to the shown embodiments and examples 3 westermark p benson m d buxbaum j n et al amyloid 2002 9 197 200 4 mclaurin j yang d yip c m et al j struct biol 2000 130 259 270 6 mclhinney r a j cdadwixk j k and pelly s j biochim 1987 244 109 115 8 hermansen l f bergman t jornvall h et.